Immunotherapy safety: What have we learned from surveillance surveys?

Current Allergy and Asthma Reports

Volumn 13, Issue 4, 2013, Pages 381-388

  Kannan, Jennifer A ^a   Epstein, Tolly G ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Epinephrine; Fatalities; Near fatal reactions; Peak pollen seasons; Risk factors; Safety; Subcutaneous allergen immunotherapy; Surveillance; Surveillance surveys; Uncontrolled asthma

Indexed keywords

ADRENALIN; ALLERGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PREDNISONE; PROPRANOLOL; TIMOLOL;

ABDOMINAL DISEASE; ANAPHYLAXIS; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; DISEASE CONTROL; DISEASE COURSE; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED PRACTICE; GLAUCOMA; HUMAN; HYPOTENSION; INAPPROPRIATE PRESCRIBING; INCIDENCE; INJECTION; LUNG FUNCTION; POLLEN; PRACTICE GUIDELINE; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SIDE EFFECT; SKIN TEST; STRIDOR; SUBCUTANEOUS IMMUNOTHERAPY; TIME TO TREATMENT; TREATMENT RESPONSE; URTICARIA; WHEEZING;

ALLERGENS; ANAPHYLAXIS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; EPINEPHRINE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INCIDENCE; INJECTIONS, SUBCUTANEOUS; POLLEN; RISK FACTORS;

EID: 84881174929     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0353-0     Document Type: Article

References (34)

1. Fitzhugh DJ, Lockey RF. Allergen immunotherapy: a history of the first 100 years. Curr Opin Allergy Clin Immunol. 2011;11:554-9.
2. Noon L. Prophylactic inoculation against hay fever. Historical document. Ann Allergy. 1960;18:287-91.
3. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79:660-77.
4. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol. 1993;92:6-15.
5. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;34:527-31.
6. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy. 2006;36:254-60.
7. Lamson R. Sudden death associated with the injection of foreign substances. JAMA. 1924;82:1091-8.
8. Lamson R. So-called fatal anaphylaxis in man. JAMA. 1929;93:1775-8.
9. •• Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol. 2010;104:530-5. This was the first prospective national surveillance study on SCIT safety in the United States.
10. •• Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2. Ann Allergy Asthma Immunol. 2011;107:426-431.e1. This study summarizes findings from the second year of the national prospective study on SCIT safety in the United States, with a specific focus on delayed-onset reactions.
11. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113:1129-36.
12. Committee on the Safety of Medicines (CSM) in Great Britain. CSM Update: desensitising vaccines. Br Med J (Clin Res Ed) 1986;293:948.
13. Bernstein DI, Epstein T. Systemic reactions to subcutaneous allergen immunotherapy. Immunol Allergy Clin N Am. 2011;31:241-9. viii-ix.
14. •• Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, year 3: what practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol. 2013;110:274-278.e1. This study summarizes findings from the third year of the national prospective surveillance study on SCIT safety in the United States. It provides the most updated information on the incidence of SCIT-related reactions and risk factors.
15. Joint Task Force on Practice Parameters. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2003;90:1-40.
16. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006;117:169-75.
17. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61 Suppl 82:1-20.
18. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125:569-74, 574.e1-574.e7.
19. •• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2010;127:S1-55. This is the most recent update of the Allergen Immunotherapy Practice parameter guidelines regarding immunotherapy administration and safety.
20. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD001186.pub2.
21. Boughton T. Anaphylactic death in asthmatics. JAMA. 1919;73:1912-5.
22. Lin MS, Tanner E, Lynn J, Friday Jr GA. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy. 1993;71:557-62.
23. Tinkelman DG, Cole 3rd WQ, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol. 1995;95:8-14.
24. Ponda P, Mithani S, Kopyltsova Y, et al. Allergen immunotherapy practice patterns: a worldwide survey. Ann Allergy Asthma Immunol. 2012;108:454-459.e7.
25. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126:477-480.e1-e42.
26. Liss GM, Murphy-Berendts K, Epstein T, Bernstein DI. Factors associated with severe versus mild immunotherapy-related systemic reactions: A case-referent study. J Allergy Clin Immunol 2011;127:1298-300.
27. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol. 2004;113:1117-21.
28. Matloff SM, Bailit IW, Parks P, Madden N, Greineder DK. Systemic reactions to immunotherapy. Allergy Proc. 1993;14:347-50.
29. Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Eur Ann Allergy Clin Immunol. 2004;36:52-5.
30. Rank MA, Oslie CL, Krogman JL, Park MA, Li JT. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc. 2008;29:400-5.
31. Gastaminza G, Algorta J, Audicana M, Etxenagusia M, Fernandez E, Munoz D. Systemic reactions to immunotherapy: influence of composition and manufacturer. Clin Exp Allergy. 2003;33:470-4.
32. Lang DM, Alpern MB, Visintainer PF, Smith ST. Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both beta-blocker exposure and cardiovascular disorders. Arch Intern Med. 1993;153:2033-40.
33. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med. 1991;115:270-6.
34. Rueff F, Przybilla B, Bilo MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124:1047-54.